Clearside Biomedical filings document the company's ophthalmology business, common stock structure and formal corporate-status disclosures. Its records include Form 15 notice covering termination or suspension of Exchange Act reporting duties for its common stock, 8-K material-event reports, proxy materials for stockholder votes, and amendments to its certificate of incorporation.
The filing record also covers capital-structure changes, including a one-for-fifteen reverse stock split and reduced authorized common shares, Nasdaq continued-listing matters, royalty and milestone-payment agreements tied to XIPERE and SCS Microinjector technology, operating and financial results, governance procedures and risk-related event disclosure.
Clearside Biomedical, Inc. reported that on August 28, 2025 it received a Nasdaq notice that its common stock no longer meets the Nasdaq Global Market’s minimum Market Value of Listed Securities requirement of $50,000,000. The notice does not immediately affect trading, and the company has until February 24, 2026 to regain compliance by maintaining an MVLS of at least $50,000,000 for 10 consecutive business days.
The company is already in the hearings process after a prior Nasdaq staff determination to delist its shares for failing to meet the $1.00 minimum bid price rule. To address this, stockholders approved a proposal at a special meeting on August 29, 2025 authorizing the board to implement a reverse stock split in a range of 1‑for‑5 to 1‑for‑15 and to proportionally reduce authorized common shares. The proposal passed with 46,485,055 votes for, 2,220,186 against, and 458,996 abstentions out of 49,164,237 shares represented.
Clearside Biomedical (CLSD) reported cash and cash equivalents of $9.4 million as of June 30, 2025 and total assets of $15.3 million, against total liabilities of $64.1 million, driven largely by a $55.7 million liability related to the sale of future royalties. The company recorded a $12.7 million net loss for the six months ended June 30, 2025 and an accumulated deficit of $368.0 million. License and other revenue for the six months was $2.8 million, including a $1.5 million milestone from Arctic Vision.
In July 2025 the company initiated a formal strategic review and retained Piper Sandler, paused internal R&D and implemented a workforce reduction, estimating third-quarter severance charges of approximately $2.6 million. Management states that, based on current plans, cash on hand is insufficient to fund operations for the next 12 months, and the company disclosed substantial doubt about its ability to continue as a going concern. The company also failed to regain Nasdaq's $1.00 minimum bid requirement and expects a delisting notice, while seeking stockholder approval for a possible reverse split.
Clearside Biomedical (CLSD) has called a 29 Aug 2025 Special Meeting to vote on one item: authorising its Board, within the next 12 months, to implement a reverse stock split at any ratio from 1-for-5 to 1-for-15 and to cut authorised common shares proportionally. The move is designed to lift the share price above Nasdaq’s $1.00 bid-price minimum after CLSD received a non-compliance notice on 7 Feb 2025; delisting could occur after 6 Aug 2025 if the price is not restored. A split would shrink the 78.5 M shares outstanding to 15.7 M–5.2 M and trim authorised shares from 400 M to 80 M–26.7 M. Fractional interests will be cashed out. Brokers may vote uninstructed street-name shares because the proposal is deemed “routine,” so only a simple majority of votes cast is required. Ownership percentages, rights and par value ($0.001) remain unchanged, while equity plan reserves and option exercise prices adjust mechanically. The Board can abandon the action if market conditions improve. Management warns that liquidity might fall, odd lots may form and the post-split price is not guaranteed, but believes maintaining the Nasdaq listing and investor visibility outweigh those risks. Record date: 28 Jul 2025.